β-adrenergic antagonist, clinically effective in the treatment of angina pectoris and some arrhythmias.
Sold with the permission of AstraZeneca UK Ltd.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 100 mM in water|
Preparing Stock Solutions
The following data is based on the product molecular weight 265.78. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.76 mL||18.81 mL||37.63 mL|
|5 mM||0.75 mL||3.76 mL||7.53 mL|
|10 mM||0.38 mL||1.88 mL||3.76 mL|
|50 mM||0.08 mL||0.38 mL||0.75 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
If you know of a relevant reference for Pronethalol hydrochloride, please let us know.
View Related Products by Product Action
Keywords: Pronethalol hydrochloride, supplier, β-adrenoceptor, beta-adrenoceptors, β-adrenergic, beta-adrenergic, b-adrenoceptors, b-adrenergic, antagonists, Receptors, Non-Selective, ICI38174, AstraZeneca, ICI-38174, Non-selective, Adrenergic, Beta, Receptors, Tocris Bioscience
1 Citation for Pronethalol hydrochloride
Citations are publications that use Tocris products. Selected citations for Pronethalol hydrochloride include:
Kaya et al (2009) Coupling of β2-adrenoceptors to XLαs and Gαs: a new insight into ligand-induced G protein activation. J Pharmacol Exp Ther 329 350 PMID: 19144685
Do you know of a great paper that uses Pronethalol hydrochloride from Tocris? If so please let us know.
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.